Genmab — December 2017
-
Jeg kan se Eatwell deltager her: http://ir.genmab.com/releasedetail.cfm?ReleaseID=1050595
-
saw someone posting this Actelion article again, where the CEO was also insisting to remain independant http://epvantage.com/Universal/View.aspx?type=Story&id=688728&isEPVantage=yes
-
-
Kursen siver under lav volumen. Vi har tidligere været under 1100. Hvor langt skal vi ned denne gang. Det er vel begrænset hvor mange der vil sælge i niveau mellem 1100-1180 da vi allerede har tested området og dem der har købt for nylig sælger sikkert heller ikke.
-
@JonSnow: Læs hele historien på borsen.dk: http://borsen.dk/nyheder/virksomheder/artikel/1/355285/genmabs_topchef_analytikerne_tager_fejl_paa_flere_punkter.html#ixzz50NtX2W9o
"Analytikerne tager fejl på flere punkter, da de har for kort behandlingsvarighed med alt for få måneder indregnet, da de blandt andet ikke indregner vedligeholdelsesbehandlingen rigtigt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind